Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

In the wake of mass restructuring efforts across the Department of Health and Human Services (HHS), the FDA has missed yet another approval decision target date. | GSK had expected to secure an FDA ...

A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...

Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsLuis Sanay - Vice President, Investor ...

Explore Novavax's Q1 2025 earnings insights, highlighting raised revenue forecasts, strategic partnerships, and progress toward non-GAAP profitability ...

WASHINGTON — The Trump administration’s effort to impose new requirements on Novavax's COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus — is ...